Premium
Sensient Technologies Corp (SXT)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | Thierry HoangInitié | -400,00 | 46,08k | Vente | 115,19 | 13,91k | -2,80% |
| 2026-05-04 | Thierry HoangInitié | -439,00 | 50,11k | Vente | 114,15 | 14,31k | -2,98% |
| 2026-04-30 | Mr. Steve MorrisPresident of Color Group | -200,00 | 22,92k | Vente | 114,58 | 7,94k | -2,46% |
| 2026-04-30 | Freemont Capital Pte. Ltd.Société | -2,13M | 233,37M | Vente | 109,69 | 4,18M | -33,74% |
| 2026-04-23 | Dr. Donald W. LandryIndependent Director & Member of Scientific Advisory Committee | -674,00 | 66,88k | Sale to Issuer | 99,23 | 10,45k | -6,06% |
| 2026-04-23 | Mr. Brett W. BruggemanIndependent Director & Member of Scientific Advisory Committee | -283,00 | 28,08k | Sale to Issuer | 99,23 | 3,57k | -7,35% |
| 2026-04-23 | Dr. Mario G. FerruzziIndependent Director & Chairman of Scientific Advisory Committee | -674,00 | 66,88k | Sale to Issuer | 99,23 | 8,75k | -7,15% |
| 2026-04-23 | Ms. Carol R. JacksonIndependent Director & Member of Scientific Advisory Committee | -674,00 | 66,88k | Sale to Issuer | 99,23 | 6,54k | -9,34% |
| 2026-04-23 | Mr. Scott C. MorrisonIndependent Director & Member of Scientific Advisory Committee | -674,00 | 66,88k | Sale to Issuer | 99,23 | 11,55k | -5,52% |
| 2026-04-23 | Ms. Essie Mae WhitelawDirector & Member of Scientific Advisory Committee | -674,00 | 66,88k | Sale to Issuer | 99,23 | 17,58k | -3,69% |
| 2026-03-02 | Mr. Steve MorrisPresident of Color Group | -373,00 | 37,52k | Sale to Issuer | 100,58 | 8,09k | -4,41% |
| 2026-03-02 | Mr. Adam VanderleestVP, Controller & CAO | -133,00 | 13,38k | Sale to Issuer | 100,58 | 2,41k | -5,24% |
| 2026-02-12 | Mr. Michael C. GeraghtyMember of Scientific Advisory Committee | 2,46k | 0,00 | Derivative Exercise and Retained Stock | - | 46,35k | 5,61% |
| 2026-02-12 | Mr. Michael C. GeraghtyMember of Scientific Advisory Committee | -2,46k | 241,10k | Derivative Exercise and Sale | 97,93 | 46,35k | - |
| 2026-02-12 | Thierry HoangInitié | 1,29k | 0,00 | Derivative Exercise and Retained Stock | - | 14,75k | 9,61% |
| 2026-02-12 | Ms. Amy Schmidt JonesVP of HR & Senior Counsel | 1,69k | 0,00 | Derivative Exercise and Retained Stock | - | 25,98k | 6,98% |
| 2026-02-12 | Ms. Amy Schmidt JonesVP of HR & Senior Counsel | -1,69k | 165,89k | Derivative Exercise and Sale | 97,93 | 25,98k | - |
| 2026-02-12 | Mr. John J. ManningSenior VP, General Counsel & Secretary | 2,01k | 0,00 | Derivative Exercise and Retained Stock | - | 36,32k | 5,85% |
| 2026-02-12 | Mr. John J. ManningSenior VP, General Counsel & Secretary | -2,01k | 196,64k | Derivative Exercise and Sale | 97,93 | 36,32k | - |
| 2026-02-12 | Mr. Paul ManningChairman, CEO, President & Member of Scientific Advisory Committee | 15,01k | 0,00 | Derivative Exercise and Retained Stock | - | 280,15k | 5,66% |
| 2026-02-12 | Mr. Paul ManningChairman, CEO, President & Member of Scientific Advisory Committee | -15,01k | 1,47M | Derivative Exercise and Sale | 97,93 | 280,15k | - |
| 2026-02-12 | Mr. Tobin TornehlVP & CFO | 751,00 | 0,00 | Derivative Exercise and Retained Stock | - | 16,46k | 4,78% |
| 2026-02-12 | Mr. Tobin TornehlVP & CFO | -751,00 | 73,55k | Derivative Exercise and Sale | 97,93 | 16,46k | - |
| 2025-12-08 | Mr. Tobin TornehlVP & CFO | -586,00 | 52,75k | Sale to Issuer | 90,02 | 12,81k | -4,38% |
| 2025-12-08 | Mr. Paul ManningChairman, CEO, President & Member of Scientific Advisory Committee | -11,72k | 1,06M | Sale to Issuer | 90,02 | 245,44k | -4,56% |
| 2025-12-08 | Mr. John J. ManningSenior VP, General Counsel & Secretary | -1,57k | 141,06k | Sale to Issuer | 90,02 | 31,51k | -4,74% |
| 2025-12-08 | Ms. Amy Schmidt JonesVP of HR & Senior Counsel | -1,32k | 119,01k | Sale to Issuer | 90,02 | 22,00k | -5,67% |
| 2025-12-08 | Mr. Michael C. GeraghtyMember of Scientific Advisory Committee | -1,92k | 172,93k | Sale to Issuer | 90,02 | 40,46k | -4,53% |
| 2025-11-20 | Ms. Essie Mae WhitelawDirector & Member of Scientific Advisory Committee | -4,52k | 428,38k | Vente | 93,22 - 95,02 | 17,13k | -20,87% |
| 2025-11-04 | Mr. David J. PlautzVP of Investor Relations & Treasurer | 2,15k | 199,91k | Achat | 92,98 | 3,22k | 200,37% |
| 2025-11-03 | Dr. Joseph CarleoneIndependent Lead Director & Member of Scientific Advisory Committee | 1 000,00 | 91,26k | Achat | 91,26 | 22,41k | 4,67% |
| 2025-08-11 | Mr. Paul ManningChairman, CEO, President & Member of Scientific Advisory Committee | 20,00 | 2,34k | Achat | 116,94 | 257,15k | 0,01% |
| 2025-08-06 | Mr. Sharad P. JainIndependent Director & Member of Scientific Advisory Committee | -1,23 | 140,51 | Vente | 114,14 | 5,81k | -0,02% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
